You are here: Industry Insights > GLP-1

News List

Gut Hormone-Based Pharmacotherapies for Obesity Neeta Ratanghayra
April 28, 2024
The history of pharmacotherapy for obesity is marked by a series of promising drugs that were withdrawn due to safety concerns.
Domestic New Drug R&D Strength is Gradually Ascending, and Overseas Product Authorization is in Full Swing WND/PharmaSources
December 14, 2023
On November 13th, LEGN.US reached an 1 billion US dollar cooperation agreement with Novartis Pharmaceuticals.
Why the unit price gap of the weight loss drug GLP-1 is nearly ten times? Lao Xue/PharmaSources
May 22, 2023
GLP-1 drugs can be used for weight loss. Why the unit price difference is nearly ten times?
Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline prnasia
October 13, 2021
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the closing of an $70 million Series C financing.
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Glucagon-like Peptide-1 and Glucagon Receptor Dual Agonist in Overweight or Obese Chinese Participants at the American Diabetes Assoc prnasia
June 25, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that results of a phase 1 ...
FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 fda.gov
June 07, 2021
Today, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition for use in addition to a reduced calorie diet and increased
Moderate Physical Activity Tied to Lower Fasting GLP-1 in Men drugs
December 26, 2019
For overweight men, physical activity (PA) even at moderate intensity is associated with lower fasting and greater glucose-stimulated glucagon-like peptide-1 (GLP-1) responses ...
First oral GLP-1 treatment for type 2 diabetes approved europeanpharmaceuticalreview
September 24, 2019
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
FDA Approves Rybelsus (semaglutide), the First Oral GLP-1 Analog Treatment for Adults with Type 2 Diabetes drugs
September 23, 2019
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar (glucose).
Boehringer, Yuhan Enter NASH Pact contractpharma
July 09, 2019
To develop dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule.

Previous page 1 2 3 Next page